Navigation Links
Mitsubishi Chemical Medience and LabCorp Clinical Trials Announce Master Service Agreement to Offer Clients Greater Access to Global Central Lab Services

TOKYO, June 21, 2013 /PRNewswire/ -- Mitsubishi Chemical Medience Corporation (MCM) today announced that the company has signed a Master Service Agreement with the clinical trials division of Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH).  The agreement builds on the strengths and capabilities of both companies, and allows LabCorp Clinical Trials and MCM to extend their service offerings to clients in Japan and around the world, respectfully.

"Pharmaceutical sponsors everywhere continue to look to new markets and technologies for drug development opportunities, and our clients are no different," said Mr. Shinichi Yoshihara, President and CEO of Mitsubishi Chemical Medience Corporation.  "We are therefore excited to work closely with LabCorp as a global leader in central lab, biomarker and specialty testing, and with cutting-edge technologies from both sides we are confident this partnership will provide new channels of growth and competitive advantage for both companies."

"MCM is a leading diagnostic laboratory and central lab in Japan with considerable experience and long-standing relationships in the medical and pharmaceutical communities," said Dr. Mark Brecher, LabCorp's Chief Medical Officer.  "The two companies complement each other in this respect, and we look forward to working together to offer a complete global solution for our customers conducting trials in Japan and around the globe."

Both companies will exhibit at the Drug Information Association (DIA) annual meeting taking place June 23-27 in Boston, Mass.  Clients who are interested in learning more about this announcement can visit LabCorp Clinical Trials at booth 1451 or MCM at booth 1548.

About Mitsubishi Chemical Medience Corporation
Mitsubishi Chemical Medience Corporation is a member of the Mitsubishi Chemical Holdings Corporation Group, which is headquartered in Tokyo, Japan. Mitsubishi Chemical Medience is the first company in Japan to establish a business style that combines clinical and diagnostic laboratory testing services with in vitro diagnostics (IVD) and pharmaceutical development support. One of Mitsubishi Chemical Medience's primary business areas is their IVD business, which includes the development, sale, export, and import of in vitro diagnostic reagents and instruments. Mitsubishi Chemical Medience's globally accepted PATHFAST system, a rapid point-of-care immunochemistry analyzer, has been exported to more than 40 countries. Throughout almost five decades of IVD business, customers in various chemical and diagnostic industry segments have come to trust and rely on Mitsubishi Chemical Medience's competence and strength, as represented by the superior quality of their products and customized solutions. To learn more, visit the company's website at

SOURCE Mitsubishi Chemical Medience Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Neuland Labs Strengthens Commitment to Japanese Market With New Manufacturing Collaboration With Mitsubishi Healthcare Unit API Corporation
2. ESTEVE Announces Publication of Key Preclinical Data for a Novel Oral, First-in-class New Chemical Entity (NCE) Sigma-1 Receptor Antagonist (E-52862), that has Completed Phase I and Initiated its Phase II Clinical Trial Program
3. ChemAxon Announces New Version of for Tablet PCs
4. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
5. DOW Chemical at the World Drug Delivery & Formulation Summit 2013
6. Top Insight On Green Chemistry, API Manufacturing, Specialty Chemicals And Supply Chain Management At InformEx USA
7. InformEx Platforms Top Chemical Suppliers In The Specialty, Industrial & Pharmaceutical Ingredients Markets
8. US Animal Health Chemicals Market
9. GlaxoSmithKline and A*STARs Institute of Chemical Engineering and Sciences to Develop new Medicines for Emerging Markets
10. New Data Show PharmAthenes Recombinant Bioscavenger Binds To A Broad Spectrum Of Chemical Nerve Agents
11. Cempra, Inc. Signs Exclusive License and Development Agreement for Solithromycin with Toyama Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation in Japan
Post Your Comments:
(Date:11/30/2015)... Diplomat Pharmacy, Inc. (NYSE: DPLO ) ... Free Press as a Top Workplace , among the ... work for in 2015. ... annually, based on employee surveys rating company leadership, career opportunities, ... based solely on employee feedback. The survey is conducted by ...
(Date:11/30/2015)...  IBA Molecular North America, Inc. (IBAMNA), a U.S. ... that as of January 1, 2016, it will do ... to rebrand the company reflects a refined vision for ... close relationship with Zevacor Molecular.  Both IBAMNA and Zevacor ... Peter Burke , Vice President Sales ...
(Date:11/30/2015)... 30, 2015 Baxalta Incorporated (NYSE: ... dedicated to delivering transformative therapies to patients ... today announced the launch and first shipments ... extended circulating half-life recombinant factor VIII (rFVIII) ... ADVATE [Antihemophilic Factor (Recombinant)]. The treatment was ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... An ... directory is specialized and only includes chiropractic clinics in the US. , The ... trustworthy alternative health practitioner when back pain sets in. When people are experiencing ...
(Date:11/30/2015)... ... November 30, 2015 , ... In ... Halloween festivities, the Word of Life Christian Church of Flint, MI, hosted a ... a giant 1.25 ton pile of candy dubbed “Candy Mountain”. , A Forever ...
(Date:11/30/2015)... ... November 30, 2015 , ... During ... fundraising campaign to raise funds for its research, education, support, and advocacy efforts. ... organization’s annual funding. , The Mesothelioma Applied Research Foundation, which also goes by ...
(Date:11/30/2015)... ... November 30, 2015 , ... The ... in Dallas, TX, on January 29 and 30, 2016. The course welcomes dental ... of their practices, to learn how to better succeed in the modern dental ...
(Date:11/30/2015)... ... November 30, 2015 , ... HemoTreat™ has announced that the ... ointment to its website. , “Our goal is simple:” says Michael Blasco, HemoTreat’s ... the comparison chart and ingredient list allows our customers to quickly see why, ...
Breaking Medicine News(10 mins):